Supervised Disulfiram in the Treatment of Alcohol Use Disorder: A Commentary
Henning Krampe
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorClaudia D. Spies
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorHannelore Ehrenreich
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorHenning Krampe
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorClaudia D. Spies
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorHannelore Ehrenreich
From the Department of Anaesthesiology and Intensive Care Medicine (HK, CDS), Charité—Universitätsmedizin Berlin, Berlin, Germany; and Division of Clinical Neuroscience (HE), Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Search for more papers by this authorAbstract
Background: This commentary discusses the systematic review “The efficacy of disulfiram for the treatment of alcohol use disorder (AUD)” by Jørgensen and colleagues (2011, Alcohol Clin Exp Res DOI: 10.1111/j.1530-0277.2011.01523.x). The main focus of the commentary is on long-term effects, long-term use, and psychotherapeutic application of supervised disulfiram.
Methods: A brief qualitative overview is given of previous and recent clinical studies on disulfiram in alcoholism treatment.
Results: The alcohol deterrent disulfiram is an effective pharmacological adjunct to the treatment of AUD when it is administered as supervised low-dose disulfiram and is integrated in comprehensive biopsychosocial alcoholism therapy. However, the assumed underlying psychological effects of psychotherapeutic disulfiram application have never been properly investigated. Prospective long-term follow-up studies are rare and suggest that long-term effects of disulfiram are associated with long-term use and/or integration of the medication in cognitive behavior therapy.
Conclusions: Evidence from decades of research suggests psychological effects as principal mode of action of supervised disulfiram. Future randomized controlled trials are needed that investigate psychological actions and long-term outcomes of this alcohol deterrent.
References
- Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift RM, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003–2017.
- Azrin NH (1976) Improvements in the community-reinforcement approach to alcoholism. Behav Res Ther 14: 339–348.
- Azrin NH (1993) Disulfiram and behavior therapy: a social-biochemical model of alcohol abuse and treatment, in Treatment Options in Addiction: Medical Management of Alcohol and Opiate Abuse ( C Brewer ed), pp 19–28. Gaskell (Royal College of Psychiatrists), London.
- Azrin NH, Sisson RW, Meyers R, Godley M (1982) Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry 13: 105–112.
- Barth S, Malcom R (2010) Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets 9: 5–12.
- Berglund M (2005) A better widged? Three lessons for improving addiction treatment from a meta-analytical study. Addiction 100: 742–750.
- Bouza C, Angeles M, Munoz A, Amate J (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99: 811–828.
- Brewer C (2005) Supervised disulfiram is more effective in alcoholics than naltrexone or acamprosate or even psychotherapy: how it works and why it matters. Adicciones 17: 285–296.
- Brewer C, Meyers RJ, Johnsen J (2000) Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs 14: 329–341.
- Brewer C, Streel E (2003) Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive “immersion” methods of foreign language teaching. Subst Abus 24: 157–173.
- Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89.
- De Sousa A, De Sousa A (2004) A one-year pragmatic trial of naltrexone versus disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 39: 528–531.
- De Sousa A, De Sousa A (2005) An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 40: 545–548.
- De Sousa A, De Sousa A (2008) An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence. J Subst Use 3: 382–388.
- De Sousa A, De Sousa J, Kapoor H (2008) An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 34: 460–463.
- Ehrenreich H, Mangholz A, Schmitt M, Lieder P, Völkel W, Rüther E, Poser W (1997) OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach. Eur Arch Psychiatry Clin Neurosci 247: 51–54.
- Finney JW, Monahan SC (1996) The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alcohol 57: 229–243.
- Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449–1455.
- Fuller RK, Gordis E (2004) Does disulfiram have a role in alcoholism treatment today? Addiction 99: 21–24.
- Gerrein JR, Rosenberg CM, Manohar V (1973) Disulfiram maintenance in outpatient treatment of alcoholism. Arch Gen Psychiatry 28: 798–802.
- Hughes JC, Cook CCH (1997) The efficacy of disulfiram—a review of outcome studies. Addiction 92: 381–395.
- Johnson BA (2011) Response to Mueller and Banas letter. Am J Psychiatry 168: 98–99.
- Jørgensen CH, Pedersen B, Tønnesen H (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res DOI: 10.1111/j.1530-0277.2011.01523.x.
- Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot J, Reynaud M, Lépine J (2008) New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11: 425–438.
- Krampe H, Ehrenreich H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 16: 2076–2090.
- Krampe H, Stawicki S, Hoehe MR, Ehrenreich H (2007) Outpatient Long-term Intensive Therapy for Alcoholics (OLITA): a successful biopsychosocial approach to the treatment of alcoholism. Dialogues Clin Neurosci 9: 399–412.
- Krampe H, Stawicki S, Ribbe K, Wagner T, Bartels C, Kröner-Herwig B, Ehrenreich H (2008) Development of an outcome prediction measure for alcoholism therapy by multimodal monitoring of treatment processes. J Psychiatr Res 43: 30–47.
- Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Ruether E, Poser W, Ehrenreich H (2006) Follow-up of 180 chronic alcoholic patients for up to seven years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 30: 86–95.
- Kristenson H (1995) How to get the best out of Antabuse. Alcohol Alcohol 30: 775–783.
- Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28: 51–63.
- Miller WR, Wilbourne PL (2002) Mesa Grande: a methodological analysis of clinical trials of treatment for alcohol use disorders. Addiction 97: 265–277.
- Mueller C, Banas R (2011) Disulfiram: an anticraving substance? Am J Psychiatry 168: 98.
- Mueser KT, Noordsy DL, Fox L, Wolfe R (2003) Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12: 242–252.
- Ojehagen A, Skjaerris A, Berglund M (1991) Long-term use of aversive drugs in outpatient alcoholism treatment. Acta Psychiatr Scand 84: 185–190.
- Pani P, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M (2010) Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev Jan 20;(1): CD007024.
- Petrakis I, Poling J, Levinson C, Nich C, Rounsaville B (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57: 1128–1137.
- Srisurapanont M, Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8: 267–280.
- Suh J, Pettinati H, Kampman K, O’Brien C (2006) The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26: 290–302.
- Tønnesen H, Rosenberg J, Nielsen H, Rasmussen V, Hauge C, Pedersen I, Kehlet H (1999) Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ 318: 1311–1316.
- Vocci F, Elkashef A (2005) Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 18: 265–270.
- Wright C, More R (1990) Disulfiram treatment of alcoholism. Am J Med 88: 647–655.
